The rebirth of epitope-based patent claims

CONCLUSIONS: Companies developing therapeutic antibodies or T cell receptors need to consider these developments in their strategic planning.PMID:38640147 | DOI:10.3233/HAB-240006

Source: Human Antibodies - April 19, 2024 Category: Biochemistry Authors: Ulrich Storz Source Type: research